Entering text into the input field will update the search result below

Minerva up premarket on trial results

Jan. 22, 2015 9:21 AM ETMinerva Neurosciences, Inc. (NERV) StockBy: Douglas W. House, SA News Editor
  • Thinly-traded nano cap Minerva Neurosciences (NASDAQ:NERV) is up 20% premarket (volume unknown) in response to its report of positive results from a Phase 1 trial assessing MIN-202 for the treatment on insomnia. Trial subjects with co-morbid insomnia related to major depressive disorder (MDD) experienced significant improvements in sleep onset and duration.
  • The Phase 1b portion was a double-blind, placebo-controlled, randomized, four-way crossover, single dose trial involved 20 male and female patients with MDD and insomnia. The primary endpoint was latency to persistent sleep (LPS). Preliminary results showed a statistically significant effect on LPS in all three doses tested (10 mg, 20 mg and 40 mg) and prolonged sleep duration of ~45 minutes.
  • MIN-202 is an orexin-2 antagonist. Its value proposition is improved safety, better restoration of sleep architecture and improved continuity compared to GABA-mimetics like Ambien (SNY).
  • MIN-202 is being developed in collaboration with Janssen Pharmaceutica NV.

Recommended For You

More Trending News

About NERV Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NERV--
Minerva Neurosciences, Inc.